Aastrom puts heart stem cell study on hold after patient dies
This article was originally published in Scrip
Executive Summary
A patient in Aastrom Biosciences's Phase II trial of a stem cell treatment for dilated cardiomyopathy (DCM) has died, prompting the company and the US FDA to put the trial on hold. The cause of death has not yet been determined and investigations are underway.